K562 cells were the first human immortalised myelogenous leukemia line to be established. K562 cells are of the erythroleukemia type, and the line is derived from a 53 year old female CML patient in blast crisis. The cells are non-adherent and rounded, are positive for the bcr:abl fusion gene, and bear some proteomic resemblance to both undifferentiated granulocytes and erythrocytes.
In culture they exhibit much less clumping than many other suspension lines, presumably due to the downregulation of surface adhesion molecules by bcr:abl. However, another study suggests that bcr:abl over-expression may actually increase cell adherence to cell culture plastic. K562 cells can spontaneously develop characteristics similar to early-stage erythrocytes, granulocytes and monocytes and are easily killed by natural killer cells as they lack the MHC complex required to inhibit NK activity. They also lack any trace of Epstein-Barr virus and other herpesviruses. In addition to the Philadelphia chromosome they also exhibit a second reciprocal translocation between the long arm of chromosome 15 with chromosome 17.
- Lozzio, C.B.; Lozzio, B.B. (1975), "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome", Blood 45 (3): 321–34, PMID 163658
- Drexler, H.G. (2000), The Leukemia-Lymphoma Cell Line Factsbook, San Diego: Academic Press
- Klein, E.; Ben-Bassat, H.; Neumann, H.; Ralph, P.; Zeuthen, J.; Polliack, A.; Vánky, F. (1976), "Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia", International Journal of Cancer 18 (4): 421–31, doi:10.1002/ijc.2910180405, PMID 789258
- Andersson, L.C.; Nilsson, K.; Gahmberg, C.G. (1979), "K562 - A human erythroleukemic cell line", International Journal of Cancer 23 (2): 143–7, doi:10.1002/ijc.2910230202, PMID 367973
- Jongen-Lavrencic, M (2005). "BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells". Leukemia 19 (3): 373–380. PMID 15674360.
- Karimiani, EG; Marriage, F; Merritt, AJ; Burthem, J; Byers, RJ; Day, PJ (Mar 2014). "Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.". Experimental hematology 42 (3): 183–191.e5. PMID 24269846.
- Lozzio, B.B.; Lozzio, C.B.; Bamberger, E.G.; Feliu, A.S. (1981), "A multipotential leukemia cell line (K-562) of human origin", Proceedings of the Society for Experimental Biology and Medicine 166 (4): 546–50, doi:10.3181/00379727-166-41106, PMID 7194480
- Lozzio, B.B.; Lozzio, C.B. (1979), "Properties and usefulness of the original K-562 human myelogenous leukemia cell line", Leukemia Research 3 (6): 363–70, doi:10.1016/0145-2126(79)90033-X, PMID 95026
- Britten, C.M.; Meyer, R.G.; Kreer, T.; Drexler, I.; Wölfel, T.; Herr, W. (2002), "The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays", Journal of Immunological Methods 259 (1–2): 95–110, doi:10.1016/S0022-1759(01)00499-9, PMID 11730845
- Clark, R.E.; Dodi, I.A.; Hill, S.C.; Lill, J.R.; Aubert, G.; Macintyre, A.R.; Rojas, J.; Bourdon, A. et al. (2001), "Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein", Blood 98 (10): 2887–93, doi:10.1182/blood.V98.10.2887, PMID 11698267
|This cell biology article is a stub. You can help Wikipedia by expanding it.|